274 related articles for article (PubMed ID: 32766875)
1. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
Kim SJ; Lim JQ; Laurensia Y; Cho J; Yoon SE; Lee JY; Ryu KJ; Ko YH; Koh Y; Cho D; Lim ST; Enemark MB; D'Amore F; Bjerre M; Ong CK; Kim WS
Blood; 2020 Dec; 136(24):2754-2763. PubMed ID: 32766875
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
3. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).
Tao R; Fan L; Song Y; Hu Y; Zhang W; Wang Y; Xu W; Li J
Signal Transduct Target Ther; 2021 Oct; 6(1):365. PubMed ID: 34702811
[TBL] [Abstract][Full Text] [Related]
5. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Dirix LY; Takacs I; Jerusalem G; Nikolinakos P; Arkenau HT; Forero-Torres A; Boccia R; Lippman ME; Somer R; Smakal M; Emens LA; Hrinczenko B; Edenfield W; Gurtler J; von Heydebreck A; Grote HJ; Chin K; Hamilton EP
Breast Cancer Res Treat; 2018 Feb; 167(3):671-686. PubMed ID: 29063313
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
[TBL] [Abstract][Full Text] [Related]
7. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
8. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract][Full Text] [Related]
9. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
[TBL] [Abstract][Full Text] [Related]
11. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
12. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.
Herrera AF; Burton C; Radford J; Miall F; Townsend W; Santoro A; Zinzani PL; Lewis D; Fowst C; Brar S; Huang B; Thall A; Collins GP
Blood Adv; 2021 Sep; 5(17):3387-3396. PubMed ID: 34477818
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
14. Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.
Kim SJ; Ryu KJ; Park B; Yoon SE; Cho J; Park Y; Kim WS
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428710
[TBL] [Abstract][Full Text] [Related]
15. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.
Cai J; Liu P; Huang H; Li Y; Ma S; Zhou H; Tian X; Zhang Y; Gao Y; Xia Y; Zhang X; Yang H; Li L; Cai Q
Signal Transduct Target Ther; 2020 Dec; 5(1):289. PubMed ID: 33376237
[TBL] [Abstract][Full Text] [Related]
16. Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.
Shi W; Lu T; Xu-Monette Y; Young KH
Chin Clin Oncol; 2024 Feb; 13(1):17. PubMed ID: 38073311
[No Abstract] [Full Text] [Related]
17. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH
J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Rong QX; Wang F; Guo ZX; Hu Y; An SN; Luo M; Zhang H; Wu SC; Huang HQ; Fu LW
Mol Cancer; 2021 May; 20(1):80. PubMed ID: 34051805
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.
Huang H; Zhu J; Yao M; Kim TM; Yoon DH; Cho SG; Eom HS; Lim ST; Yeh SP; Song Y; Kwong YL; Kim JS; Jin J; Shi Y; Kim H; Qing M; Zhou T; Gao G; Dong Z; Qi M; Kim WS
J Hematol Oncol; 2021 Feb; 14(1):25. PubMed ID: 33588922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]